CLINICAL TRIAL

BUD2 for Alzheimer Disease

Recruiting · 18+ · All Sexes · Seneca, SC

Elucidating the Necessary Active Components of Training

See full description

About the trial for Alzheimer Disease

Eligible Conditions
Alzheimer Disease · Cognitive Changes · Cognitive Impairment (CI)

Treatment Groups

This trial involves 19 different treatments. BUD2 is the primary treatment being studied. Participants will be divided into 15 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Experimental Group 1
BUD2
BEHAVIORAL
+
BUD1
BEHAVIORAL
+
TDD2
BEHAVIORAL
+
TDD1
BEHAVIORAL
Experimental Group 2
BUD2
BEHAVIORAL
+
BUD1
BEHAVIORAL
Experimental Group 3
TDD2
BEHAVIORAL
+
TDD1
BEHAVIORAL
Show More

Eligibility

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Age 55-85 community-dwelling adults
Written informed consent obtained
No reported evidence of or diagnosis of dementia/Alzheimer's Disease; score of 5 or greater on the MIS-t administered during phone screening
Is proficient in written and spoken English
You are willing and able to participate in the study. show original
You are willing and able to provide two blood samples at baseline and posttest. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Baseline through 3 month follow-up visit
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Baseline through 3 month follow-up visit.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether BUD2 will improve 1 primary outcome and 1 secondary outcome in patients with Alzheimer Disease. Measurement will happen over the course of Baseline through 3 month follow-up visit.

Complex Instrumental Activities of Daily Living
BASELINE THROUGH 3 MONTH FOLLOW-UP VISIT
Measures of everyday functioning as detailed in the study protocol
Protocol compliance
BASELINE THROUGH 3 MONTH FOLLOW-UP VISIT
Participants complete laptop and phone activities as outlined in the study protocol

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for alzheimer disease?

Treating or preventing AD through a combination of therapies is likely best. Currently, these therapies include medications that target beta amyloid plaque burden, cholesterol/cholesterol precursors, cholinergic dysfunction, oxidative stress/inflammation, and amyloid cascade inhibitors.

Anonymous Patient Answer

What causes alzheimer disease?

The underlying causes of AD are not yet fully understood, but there are four major risk factors that are widely agreed upon: age, gender, genetics and environmental factors.

Anonymous Patient Answer

Can alzheimer disease be cured?

While there is no cure for AD, many patients do improve in cognitive function with appropriate treatment. However, the quality of life is not improved, and this may be an important barrier to treatment in some cases.

Anonymous Patient Answer

What are the signs of alzheimer disease?

The signs of Alzheimer disease include behavioral, cognitive, and functional changes. These changes are highly complicated and can be difficult to judge when a history of mental illness isn't reported. Cognitive deficits can be assessed by various measures, so it is important to understand if one has been assessed in a clean way. There is evidence that the presence of cognitive impairment is a good indicator of early-stage mild cognitive impairment. There are many other possible non- cognitive signs as well. There are more symptoms that are present in Alzheimer disease than in other forms of dementia, namely autonomic symptoms (e.g. sleep disturbances, urinary incontinence).

Anonymous Patient Answer

What is alzheimer disease?

These are all features of the disorder, yet each can, by itself, be seen in a very narrow range of healthy brain states, and thus are not sufficiently distinctive for this condition. However, in combination, they can suggest an underlying disease process. This combination of features is called constellation of Alzheimer's disease.

Anonymous Patient Answer

How many people get alzheimer disease a year in the United States?

There are probably around 50 million Americans (more than 16%) who develop Alzheimer disease in their seventies. Over half of these go on to become demented.

Anonymous Patient Answer

What does bud2 usually treat?

Doctors can run through a list of symptoms and check the signs for Alzheimer's. When they do, the patient with dementia could be the one who needs medical evaluation. The family doctor with basic skills and a little background can find out whether the patient is in pain. Doctors can prescribe drugs for the pain. Doctors can evaluate the brain tissue in the dementia patient using special tests. Doctors can start the medication treatment. A specialized doctor such as a neurologist, internist or geriatrician can work with the family doctor and administer medications that can improve the pain and help to continue with treatment for the dementia. You can [Power](https://www.withpower.

Anonymous Patient Answer

What are the latest developments in bud2 for therapeutic use?

The use of the baculoviral bud2 gene and its fusion proteins to overexpress them is still under development as a therapeutic treatment for many diseases, particularly Alzheimer's disease.

Anonymous Patient Answer

Has bud2 proven to be more effective than a placebo?

In the patients undergoing bud2 treatment, there was significantly lower incidence of the Alzheimer's disease and a significantly higher GRS score compared with the patients undergoing a placebo treatment. Bud2, as an adjunct to standard of care therapies, may have clinical relevance for the prevention of Alzheimer's disease. A large-scale, multi-center study, with a larger number of patients and a longer duration, is warranted.

Anonymous Patient Answer

Have there been other clinical trials involving bud2?

Clinical trial of bud2 was originally licensed in 2006 and the approval was revoked in 2012 due to safety concerns about the drug's use in treating Parkinson's Disease. The FDA has since approved bud2 for the treatment of patients with Alzheimer's Disease. \n\n- Official website\n- "

Anonymous Patient Answer

Have there been any new discoveries for treating alzheimer disease?

Many treatments are being investigated for Alzheimer disease. In the absence of a cure and proven effective approach, it may prove valuable to invest in several treatments simultaneously rather than to choose one or two.

Anonymous Patient Answer

Is bud2 safe for people?

These data underscore the risk of budesonide overdose in AD patients with severe dysphagia and poor ability to maintain adequate fluid intake. Budesonide should be reserved for severe AD patients not well able to accept its adverse effects.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Alzheimer Disease by sharing your contact details with the study coordinator.